Levetiracetam (lev-eh-teer-ASS-eh-tam)
Brand name: Keppra® (KEP-ruh), Keppra XR™ (KEP-ruh-eks-arr)

Background for Health Care Provider:
Levetiracetam is almost completely absorbed from the small intestine and has 100% bioavailability in tablet and solution forms. Food does not interact with its absorption; however, for best therapeutic outcomes patients should take the medication consistently with food or on an empty stomach. Levetiracetam is not significantly protein bound in plasma, and there are, therefore, no clinically significant binding interactions with other drugs. Levetiracetam is primarily cleared by the kidneys (~66%), but is metabolized to a small extent to metabolites of little clinical significance. Data currently does not indicate clinically significant changes in levetiracetam clearance due to hepatic enzyme induction or inhibition.

Effect of Other Drugs on Levetiracetam Serum Levels:
- **Decrease Levetiracetam Serum Levels**
  - No known clinically significant interactions
- **Increase Levetiracetam Serum Levels**
  - No known clinically significant interactions

Effect of Levetiracetam on Other Drugs' Serum Levels:
- **Increase Other Serum Drug Levels**
  - No known clinically significant interactions
- **Decrease Other Serum Drug Levels**
  - No known clinically significant interactions

Ryan F. Miller  
Doctor of Pharmacy Candidate 2007  
University of Wisconsin School of Pharmacy  
September 2008  
Steven C. Schachter, MD